Introduction
Chronic myelogenous leukemia (CML) is a clonal disorder originated from multipotential hematopoietic stem cells, which shows excessive proliferation of differentiated myeloid cells (Deininger et al., 2000; Ren, 2005) . The clinical course of the disease is characterized by its hematologically and temporally distinct stages (Deininger et al., 2000; Ren, 2005) . In the initial stage, chronic phase (CP), the disease is indolent and the leukemic cells retain an ability to differentiate into mature myeloid cells. After several years of the chronic phase, however, the disease inevitably accelerates and ultimately progresses to the terminal fatal stage, blast crisis (BC), which involves rapid expansion of differentiation-arrested blast cells.
Cytogenetically, CML CP is associated with the Ph chromosome, a shortened chromosome 22, resulting from a reciprocal chromosomal translocation between chromosome 9 and 22 (t(9;22)(q34;q11); Rowley, 1973) . This fuses 5 0 portion of BCR gene to 3 0 portion of ABL proto-oncogene, thereby creating BCR/ABL chimeric mRNA encoding 210 kDa hybrid protein (p210BCR/ ABL). p210BCR/ABL possesses a constitutively active kinase activity, which is believed to initiate CP. In contrast, mechanism responsible for transition from CP to BC remains poorly understood, although the appearance of nonrandom chromosomal abnormalities in BC strongly suggests that additional events would account for disease progression (Deininger et al., 2000; Ren, 2005) .
To understand the complex clinical course of human CML, it is necessary to develop animal models. Major attempts have been focused on bone marrow transplantation (BMT) experiments. Transplantation of BM cells infected with p210BCR/ABL-expressing retroviruses into irradiated mice induced rapid proliferation of differentiated myeloid cells (Pear et al., 1998; Zhang and Ren, 1998; Li et al., 1999) . On the other hand, transgenic mice (Tg) expressing p210BCR/ABL under various promoters also provided useful models (Honda et al., 1995 (Honda et al., , 1998 Voncken et al., 1995; Huettner et al., 2000 Huettner et al., , 2003 Koschmieder et al., 2005) . We generated Tg-expressing p210BCR/ABL under the control of mouse TEC promoter (Honda et al., 1997) and demonstrated that the transgenic progeny reproducibly exhibited a myeloproliferative disorder closely resembling to human CML (Honda et al., 1998) . We then crossed p210BCR/ABL Tg with p53 heterozygous mice and demonstrated that acquired and preferential loss of p53 in p210BCR/ABL-expressing hematopoietic cells induced BC (Honda et al., 2000) . In addition, we crossed p210BCR/ABL Tg with Dok-1/Dok-2 knockout mice and showed that the absence of Dok-1 and Dok-2 accelerated disease phenotype and caused BC, demonstrating that Dok-1 and Dok-2 function as tumor suppressors (Niki et al., 2004) . Based on these results, our p210BCR/ABL Tg can be regarded as a useful model for investigating molecular mechanism(s) underlying the progression from CML CP to BC.
In this report, to identify gene(s) whose altered expression contributes to disease evolution of CML, we employed retroviral insertional mutagenesis to the p210BCR/ABL Tg, by directly injecting Moloney murine leukemia virus (MMLV; Jonkers and Berns, 1996) and its derivative, MOL4070LTR (Wolff et al., 2003b) , into newborn mice.
Results
MMLV induced T-cell ALL in p210BCR/ABL Tg with a higher incidence and in a shorter period than wild-type littermates MMLV-injection induced acute leukemia in both p210BCR/ABL Tg and wild-type littermates (WT), but the disease frequency and latency were significantly different between the two groups. As shown in Figure 1a , in contrast that WT injected with MMLV (WT/MMLV) developed acute leukemia after 5 months after birth (dotted line), p210BCR/ABL Tg injected with MMLV (p210BCR/ABL/MMLV) began to develop acute leukemia at as early as 2 months of age and all Tg died within 4 months of age (thick line). All the leukemic mice exhibited massive thymoma and splenomegaly, and pathological analysis showed proliferation of blast cells in the peripheral blood, thymus, spleen and other tissues. Since the leukemic cells exclusively expressed a T-cell antigen, they were diagnosed as T-cell ALL (T-ALL). The representative results of pathological and flow cytometric analyses of a T-ALL mouse (MMLV-2) are shown in Figure 2a (left panel) and Figure 2b (upper panel), respectively, and characteristics of p210BCR/ABL/MMLV leukemic mice are summarized in Table 1 .
MOL4070 induced T-cell and B-cell ALL in p210BCR/ ABL Tg while no disease was observed in WT MOL4070LTR injection induced acute leukemia in 6 of 11 p210BCR/ABL Tg (p210BCR/ABL/MOL4070), while no disease was observed in virus-injected WT (Figure 1b) . Among the diseased mice, three (MOL4070-3, -4 and -6) showed thymic enlargement as observed in p210BCR/ABL/MMLV, whereas other three (MOL4070-1, -2 and -5) exhibited different phenotypes. MOL4070-1 developed a tumor on the right shoulder at 3 months of age. Since the tumor enlarged and the peripheral blood smear showed proliferation of blast cells, the mouse was diagnosed as acute leukemia with blastoma. The other two mice (MOL4070-2 and -5) exhibited multiple LN swellings and splenomegaly but no thymic enlargement was evident. Blast cells of the former three mice (MOL4070-3, -4 and -6) were positive for a T-cell antigen and were diagnosed as T-ALL, whereas those of the latter three mice (MOL4070-1, -2 and -5) were positive for a B-cell antigen and were considered to develop B-cell ALL (B-ALL). The representative results of pathological and flow cytometric analyses of a B-ALL mouse (MOL4070-1) are shown in Figure 2a (right panel) and 2b (lower panel), respectively, and characteristics of p210BCR/ABL/MOL4070 leukemic mice are summarized in Table 2 .
Identification of the transgene as a retrovirus common integration site in B-cell leukemias The results that retrovirus-injected p210BCR/ABL developed acute leukemia with higher morbidity and mortality than virus-injected WT (Figures 1a and b) indicated that alteration(s) in gene expression by retroviral integration cooperated with p210BCR/ABL and induced ALL. To identify virus-integrated genes, DNAs extracted from leukemic tissues were subjected to inverse PCR (iPCR). We first tried to identify retrovirus common integration sites (CISs) in B-ALL cases, since in human CML BC, B-cell crisis is more frequently observed than T-cell crisis (Pane et al., 2002) . Among iPCR fragments obtained from B-cell leukemias (MOL4070-1, -2 and -5; see Supplementary Table 2), we found one interesting PCR product in MOL4070-1, in which a retrovirus integrated in the promoter region of mouse TEC gene but sequencing of whole PCR product revealed that the sequences were interrupted and followed by human BCR/ABL cDNA. Since this exactly corresponds to the structure of the p210BCR/ABL transgene (Honda et al., 1998) , the integration site was disclosed to be not in the endogenous TEC promoter but in the promoter region of the transgene. In addition, an integration site was found in the coding region of ABL gene in MOL4070-2, but curiously the sequences had only an approximately 80% homology to mouse ABL gene but completely matched human ABL gene, indicating that the integration occurred not in the endogenous ABL gene but in the ABL-coding region of the transgene. Based on these findings, the transgene was identified as a CIS, where integrations occurred in the promoter and in the ABLcoding regions. In the latter case, the retrovirus insertion created a new stop codon at nucleotide 5116, which would produce truncated BCR/ABL. The schematic model of the integration sites and resultant protein products in these mice are shown in Figure 3a .
Overexpression of p210BCR/ABL and expression of truncated BCR/ABL with an enhanced kinase activity To examine cells with these integration sites to be a major part in the tumors, Southern blot was performed using transgene-derived fragments adjacent to the integration sites. DNA extracted from a virus-noninfected p210BCR/ABL transgenic spleen was used as a control. As shown in Figure 3b , rearranged bands were detected in both cases (indicated by arrowheads), demonstrating that these integration sites were the major integration sites and that the tumors were clonal in origin.
To investigate whether these integrations altered the expression and/or the kinase activity of p210BCR/ABL, we performed northern blot and an in vitro kinase assay using RNAs and proteins extracted from the tumors. Virus-not-infected p210BCR/ABL transgenic spleen and tumors of MOL4070-3 to -5, in which retrovirus was not integrated in the transgene, were used as controls. The results are shown in Figures 3c and d .
It is not surprising that expression of p210BCR/ABL message or phosphorylation of p210BCR/ABL protein was not detected in the control p210BCR/ABL transgenic spleen (Figures 3c and d) , since our previous data demonstrated that the basal transgene expression was quite low, probably due to the nature of the promoter used (Honda et al., 1998) . Enhanced expression of p210BCR/ABL mRNA and phosphorylation of its protein product were observed in MOL4070-1 (indicated by arrowheads in Figures 3c and d ). In addition, although no upregulation of the transgene-derived mRNA was apparent, an approximately 160 kDa phosphorylated band corresponding to the molecular weight of the truncated BCR/ABL was evident in MOL4070-2 (indicated by an arrow in Figure 3d ). These results demonstrated that retrovirus integrations in MOL4070-1 and -2 induced overexpression of p210BCR/ABL and truncated BCR/ABL with an enhanced kinase activity, respectively.
Identification of Notch1 gene as a retrovirus common integration site in T-cell leukemias
Among the genes isolated by iPCR in T-ALL cases developed in p210BCR/ABL Tg (MMLV1-10 and MOL4070-3, -4 and -6; listed on Supplementary Tables  1 and 2 ), we identified another CIS, Notch1 gene, which encodes a transmembrane protein involved in cellular signaling (Ellisen et al., 1991) . In two Notch1-integrated cases, one integration was found in the second intron (MMLV-1), while the other occurred in the coding region of the last exon (MMLV-6), which created a new stop codon at nucleotide 7114 and would produce a truncated protein lacking the C-terminal domain. The schematic model of the integration sites and protein products in the two Notch1-inserted cases is shown in Figure 4a .
Overexpression of Notch1 and expression of Notch1 lacking the C-terminal region (Notch1DC) with its activated product, C-terminal-truncated Notch1 intracellular domain (NICDDC) To investigate cells with these Notch1-integration sites to be a major population in the tumors, Southern blot was p210BCR/ABL and Notch1 expression in CML BC T Mizuno et al performed using genomic fragments adjacent to the integration sites. As shown in Figure 4b , in both MMLV-1 and MMLV-6, a rearranged band was detected (indicated as arrowheads), demonstrating these sites to be major integration sites. We next investigated possible alteration in Notch1 expression in these Notch1-inserted leukemias by northern blot using Notch1 cDNA and by western blot using an anti-Notch1 antibody, mN1A. Virus-non-injected transgenic thymus and thymomas of MMLV-3BMMLV-5, in which retrovirus was not integrated in Notch1 gene, were used as controls. As shown in Figures 4c and d (upper panels), at both mRNA and protein levels, overexpression of Notch1 was observed in MMLV-1 (indicated by an arrowhead) and expression of Notch1 lacking C-terminal region (Notch1DC) was detected in MMLV-6 (indicated by an arrow). In addition, in the western blot, since the mN1A antibody recognizes not only full-length Notch1 (>200 kDa) but also cleaved Notch1 (B120 kDa), the expressional changes of Notch1 in MMLV-1 and MMLV-6 were found to be associated with enhanced expression of Notch1 transmembrane subunit (NTM), the product after S1 cleavage and stable expression of C-terminaldeleted NTM (NTMDC), respectively (indicated by a white triangle and by an arrow in Figure 4d ). To investigate whether the altered expression of Notch1/ NTM and Notch1DC/NTMDC affected the expression of Notch1 intracellular domain (NICD), the active form of Notch1 after S3 cleavage, the same samples were blotted with Val1477 antibody that specifically recognizes NICD. As shown in the lower panel in Figure 4d , expression of NICDDC was observed in MMLV-6, whereas no apparent expression of NICD was detected in other samples including MMLV-1. These results indicated that the retrovirus insertion in MMLV-1 induced overexpression of Notch1 and NTM, whereas that in MMLV-6 resulted in expression of Notch1DC, which led to stable expression of NTMDC and NICDDC.
Double Tg for p210BCR/ABL and Notch1DC developed T-ALL with Stat5 activation We finally examined whether Notch1DC/NICDDC cooperates with p210BCR/ABL and induces acute p210BCR/ABL and Notch1 expression in CML BC T Mizuno et al leukemia in vivo. For this we generated Notch1DC Tg, crossed them with p210BCR/ABL Tg and created double Tg for both p210BCR/ABL and Notch1DC. Since MMLV-6 developed T-ALL, the lck promoter, which drives transgene expression in thymocytes (Abraham et al., 1991) , was chosen as a regulatory element and to facilitate detection of Notch1DC, a Flag-HA (FH) tag was added to the 5 0 portion of Notch1DC cDNA (Figure 5a ).
Among several transgenic lines produced, a line with high Notch1DC expression, screened by anti-FH and anti-Notch1 western blots (data not shown), was used for crossing with p210BCR/ABL Tg. The survival curves of the offspring are shown in Figure 5b . During about 6 months observation, a half of double Tg developed massive thymic enlargement showing expression of a T-cell antigen (data not shown), while none of p210BCR/ ABL or lck/Notch1DC Tg alone developed hematological disease. To examine that tumors in double transgenic mice expressed Notch1DC and p210BCR/ABL proteins, cell lysates extracted from control transgenic thymuses (p210BCR/ABL Tg (C1) and lck/Notch1DC Tg (C2)) and tumors of double transgenic mice (nos. 1-4) were blotted with anti-Notch1 and anti-ABL antibodies. As shown in upper and middle panels in Figure 5c , all the tumors in addition to C2 expressed Notch1DC/NTMDC by anti-mN1A western blot, and expression of NICDDC in these samples was confirmed by anti-Val1477 western blot. In addition, stable expression of p210BCR/ABL in the tumors was detected by anti-ABL western blot (lower panel of Figure 5c ). These results indicated the cooperative role of Notch1DC/NICDDC and p210BCR/ ABL in tumor development. We further investigated alteration in tyrosine phosphorylation in the tumors, by using an anti-phosphotyrosine (PTyr) antibody (upper panel of Figure 5d ). Two major tyrosine-phosphorylated bands were detected in the tumors (shown by an arrow and an arrowhead). The upper band (B200 kDa) was identified as tyrosine-phosphorylated p210BCR/ ABL, while lower band (B97 kDa) corresponds to molecular weight of Stat5, a signal transducer involved in p210BCR/ABL-mediated pathway. To examine (Figure 5d , lower panels).
Discussion
Carcinogenesis results from accumulation of sequential genetic changes. In this respect, CML is an appropriate disease model in which generation of p210BCR/ABL initiates CP and subsequent genetic events progress the disease to BC. To identify gene(s) responsible for disease evolution, p210BCR/ABL Tg were subjected to retrovirus insertional mutagenesis, the method that has successfully identified cooperative genes in geneengineered mice (Jonkers and Berns, 1996; Mikkers and Berns, 2003; Nakamura, 2005) . MMLV and its derivative, MOL4070LTR, were used in this study. MOL4070LTR was generated as a hybrid retrovirus by replacing a part of MMLV LTR with that of 4070A, and it possesses a property to induce myeloid disease as well as lymphoid disease (Wolff et al., 2003b) . In our study, although no myeloid disease was observed, MOL4070LTR developed T-and B-ALL in contrast MMLV exclusively induced T-ALL, confirming that MOL4070LTR has a potential to induce expanded disease phenotypes as compared to the parental MMLV. Pathological examination of the diseased mice showed that the bone marrow pictures already exhibited CML-like myeloid hyperplasia with maturation when they developed acute leukemia (a representative picture is shown in Supplementary Figure 1) . Therefore, it could be conceivable that CML already existed and alteration in gene expression induced by retrovirus integration accelerated the disease and consequently caused BC. To isolate genes responsible for disease evolution, we performed iPCR and identified two CISs: one for B-ALL and the other for T-ALL. 
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The CIS in two B-ALL cases was, interestingly, the transgene itself. The reason why the transgene was subjected to retrovirus attack remains unknown, but one possibility is that the transgene insertion in the genome might alter chromatin structure, which would consequently facilitate retrovirus integration. In these cases, overexpression of p210BCR/ABL and enhanced kinase activity of its truncated product were observed. These findings are very interesting, since double Ph, where p210BCR/ABL would be more expressed than in CP, is one of the most frequently observed chromosomal abnormalities in CML BC (Calabretta and Perrotti, 2004) and our observation provides in vivo experimental evidence that acquired overexpression or enhanced kinase activity of p210BCR/ABL induces BC. In the BMT studies, p210BCR/ABL expression by retrovirus promoters would be much more abundant than that in our transgenic model, nevertheless, the recipient mice develop a rapid and fatal proliferation of differentiated myeloid cells but rarely exhibit an acute phenotype (Pear et al., 1998; Zhang and Ren, 1998; Li et al., 1999) . These results lead us to the idea that initial p210BCR/ABL expression level affects aggressiveness and latency of CML CP, but high p210BCR/ABL expression alone is not sufficient to induce acute leukemia, and acquired overexpression/enhanced kinase activity of BCR/ABL is required for disease evolution.
In MOL4070-2, the mechanism of how C-terminal deletion of p210BCR/ABL rendered an enhanced kinase activity remains unknown. The structure of truncated BCR/ABL in MOL4070-2 very closely resembles to that of a BCR/ABL mutant isolated as possessing an enhanced kinase activity and a high transforming activity (Shore et al., 1994) . Thus, existence of a negative regulatory region in the deleted sequences or alteration in intramolecular/intermolecular interaction caused by the structural change might enhance BCR/ABL-induced kinase activity, as suggested previously (Shore et al., 1994) .
Another CIS was Notch1 gene, originally cloned as a target gene in t(7;9)(q34;q34.3). Although this rearrangement accounts for only about 1% of human T-ALL (Ellisen et al., 1991) , recent studies demonstrated mutations in Notch1 to be detected in a substantial population of T-ALL in human and also in mouse (Weng et al., 2004; Lin et al., 2006; O'Nei et al., 2006) . In both species, most of the mutations are detected in the HD (heterodimerization domain) and/or the PEST (polypeptide enriched in proline, glutamate, serine and threonine) domain, as observed in case of MMLV-6 (Figure 4a ). The expressional changes in these domains are considered to contribute to leukemogenesis by facilitating ligand-independent pathway activation and by increasing the half-life of transcriptionally active Notch1 intracellular domain (NICD; Grabher et al., 2006) and indeed, enhanced expression of NICDDC was detected in MMLV-6 (Figure 4d, lower panel) . In case of MMLV-1, although we could not detect NICD by western blot, it might be possible that the overexpression of Notch1/NTM would enhance expression of NICD. These results strongly suggest that activation of Notch1 would participate in the progression to acute phase of CML.
To confirm the contribution of Notch1DC/NICDDC to CML-BC in vivo, we generated lck/Notch1DC Tg and crossed it with p210BCR/ABL Tg. Double Tg developed acute leukemia and expression of NICDDC was detected in the tumors as well as in the thymus of a control lck/ Notch1DC Tg (Figure 5c ), demonstrating the cooperative role of Notch1DC/NICDDC with p210BCR/ABL in T-cell BC. Although T-cell crisis is rare in human CML BC, it would be intriguing to examine whether Notch1 mutations are found in CML T-cell BC cases. Since an FH-tag was added to the N terminus of Notch1DC to facilitate transgene expression, further studies will be required to clarify whether transgene-derived Notch1DC might be expressed as a membrane protein and activate downstream signaling by a ligand-dependent mechanism, or it might remain in the cytoplasm and exert its function by a ligand-independent mechanism (Bray, 2006; Ilagan and Kopan, 2007) .
In addition, in the tumors of double Tg, we demonstrated that Stat5, a molecule involved in BCR/ ABL-mediated signaling pathways (Shuai et al., 1996; Scherr et al., 2006; Ye et al., 2006) , was activated. Recent studies demonstrated that Notch and its effector, Hes, activate Stat families (Kamakura et al., 2004; Monsalve et al., 2006) . Thus, it might be possible that Stat5 functions as a downstream target and its activation would play a role in ALL development in p210BCR/ABL and Notch1DC double Tg.
In addition to these two CISs, we also identified several genes that were shown to be major integration sites in the tumors by Southern blot, which included IL21 receptor (IL21R), Ahi1, Cdk5rap2 and Lyt-2 for T-ALL and Evi3 for B-ALL (see Supplementary Figure 2 and Supplementary Tables 1 and 2 ). Although these results strongly suggest that altered expression of these genes might be involved in the disease progression, further studies will be required to clarify the roles of these genes in the pathogenesis of CML BC.
In this study, by combining our CML transgenic model with retroviral insertional mutagenesis, we demonstrated that overexpression/enhanced kinase activity of BCR/ABL and expression of Notch1DC/ NICDDC contribute to CML BC. Our results provide insights in the molecular mechanism(s) responsible for the disease evolution of human CML and find this transgenic system to be a valuable tool to identify genes whose altered expression and/or structural change cooperate with p210BCR/ABL to induce BC.
Materials and methods
Transgenic mice and retrovirus infection p210BCR/ABL Tg were generated as described (Honda et al., 1998) . lck/Notch1DC Tg were generated as follows: a fragment containing the PEST domain mouse Notch1 cDNA (a kind gift from Dr Chiba in Tokyo University) was replaced by a fragment released from BstYI5 0 /6-4 (an iPCR product of MMLV-6, where the retrovirus was integrated in the last exon p210BCR/ABL and Notch1 expression in CML BC T Mizuno et al of Notch1 gene; see Supplementary Table 1) , which created cDNA lacking the C-terminal PEST domain (Notch1DC). Flag-HA (FH) sequences were added to the 5 0 end of Notch1DC, which was subcloned into a transgenic cassette possessing the lck promoter (Abraham et al., 1991) . A fragment containing the lck promoter, FH, Notch1DC and a part of human growth hormone (hGH) gene was excised and microinjected into pronuclei of C57BL/6N mice. All the mice were kept according to the guidelines of the Institute of Laboratory Animal Science, Hiroshima University.
Preparation and infection of retrovirus were performed as described (Wolff et al., 2003a, b) . In brief, newborn mice were intraperitoneally inoculated with 100 ml of virus solution containing approximately 1 Â 10 5 virus particles.
Pathological analysis
Autopsies were performed on dead or moribund animals. Smears and stamp specimens of leukemic tissues were stained with Wright-Giemsa (WG). Tissues were fixed in 10% buffered formaldehyde and subjected to light microscopic examination. All the organs were grossly examined and representative slices were prepared for hematoxylin-eosin (HE) staining.
Flow cytometric analysis
Leukemic cells were stained with fluorescein isothiocyanate (FITC)-conjugated or phycoerythrin (PE)-conjugated monoclonal antibodies, including anti-Thy-1.2, anti-B220, anti-Gr.1 and anti-Mac1 (Pharmingen, San Diego, CA, USA) and were analysed on a FACS Calibur (Becton Dickinson, Sunnyvale, CA, USA).
Identification of retroviral integration sites
Genomic DNA was digested with BstYI (New England Biolabs Inc., Beverly, MA, USA), self-ligated and subjected to the inverse PCR as described elsewhere (Yamashita et al., 2005) . The position mapping on the mouse chromosome was carried out by BLAT searching using the UCSC Genome Bioinformatics database (http://genome.ucsc.edu) and the definition of a CIS was the same in the retroviral-tagged cancer gene database (RTCGD; http://rtcgd.abcc.ncifcrf.gov/; Akagi et al., 2004) .
Southern and northern blot
Genomic DNA was digested with appropriate restriction enzymes, separated in 0.8% agarose gel, blotted to a nylon membrane and hybridized with a 32 P-dCTP labeled probe. Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA, USA), separated in 1.2% formaldehyde gel, blotted to a nylon membrane and hybridized with a 32 P-dCTP labeled probe.
Western blot, immunoprecipitation and in vitro kinase assay Tissues were lysed in 1% Triton buffer as described (Honda et al., 1995) . For western blot, proteins were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to a nitrocellulose membrane, incubated with an appropriate antibody (1:500 for anti-Notch1 monoclonal antibody, mN1A (Santa Cruz, Santa Cruz, CA, USA); 1:1000 for anti-Notch1 polyclonal antibody, Val1477 (Cell Signaling Technology, Danvers, MA, USA); 1:1000 for anti-Flag monoclonal antibody, M2 (Sigma-Aldrich, St Louis, MO, USA); 1:500 for anti-ABL polyclonal antibody, Ab1 (Oncogene Science, Cambridge, MA, USA); 1:2000 for antiphosphotyrosine monoclonal antibody, 4G10 (a kind gift from Dr Sakai in National Cancer Center) and 1:500 for anti-Stat5 polyclonal antibody, C-17 (Santa Cruz)) and developed with the enhanced chemiluminescence (ECL) system. For immunoprecipitation, proteins were incubated with 1:200 diluted an anti-Stat5 antibody and immunoprecipitated proteins were blotted with 4G10 (1:2000) or with the same antibody (1:500). For in vitro kinase assay, protein was incubated with 1:200 diluted an anti-ABL antibody and immunoprecipitated proteins were subjected to the assay as described (Honda et al., 1995) .
